Case Presentation By: Sameer Dhalla, M.D. NYU Chief Resident
The use of erlotinib, a reversible tyrosine kinase inhibitor targeting the epidermal growth factor receptor (EGFR), is commonly used for treatment of NSCLC. ALK is a newer gene with rearrangements in multiple solid tumors including NSCLC. The subset of these patients are younger, never smokers, who generally have adenocarcinoma. Treatment can be targeted to this group of patients using crizotinib, an oral inhibitor of ALK.
Primecuts – This Week In The Journals http://t.co/ZCWg1F1Gvs
Clinical Pathological Conference 4.25.2014 – The Protocol http://t.co/Ea0JzcB11o
Primecuts – This Week In The Journals http://t.co/QdmoKaE4mX
Should Physicians Ask Patients about Guns? http://t.co/HAXjA2Erp3
Is the anti-flu effectiveness of oseltamivir in question? http://t.co/Dn3SAwS9AN